FDA’s interim assessment of the PDUFA V application review system may lend more evidence to the assertion that the review burden for “breakthrough” therapies is higher for FDA and sponsors compared to conventional products.
Breakthrough applications, while usually approved faster than other submissions, also generated many more information requests on average than applications without the designation, according to an interim assessment of...